| abstract |
A prostaglandin E 2 (PGE 2 ) binding protein, and an antibody construct and a pharmaceutical composition containing the binding protein are provided. A wild-type, chimeric, CDR-grafted and humanized antibody with high affinity for prostaglandin E 2 in vitro and in vivo, with moderate prostaglandin E 2 activity. sum, as well as antibodies or antigen binding fragments thereof are useful for inhibiting prostaglandin E 2 activity in a human subject prostaglandin E 2 activity is afflicted with disorders that are harmful. [Selection] Figure 1 |